FDA 483 - Drugs Are Us, Inc., dba Hopewell Pharmacy - March 21, 2013

This FDA Form 483 document outlines observations made during an inspection of a drug manufacturing facility. The inspection revealed deficiencies in several key areas related to current Good Manufacturing Practices (cGMP).

Firstly, the aseptic processing areas were found to have a deficient system for monitoring environmental conditions. This indicates a potential risk to product sterility and quality, as the facility may not be adequately tracking or controlling critical environmental parameters necessary for aseptic operations.

Secondly, the clothing worn by personnel engaged in the processing of drug products was deemed inappropriate for the duties they perform. This observation suggests a failure to maintain adequate gowning procedures, which are crucial for preventing contamination of drug products, particularly in controlled or sterile environments.

Lastly, the facility was cited for not testing an adequate number of batches of each drug product to determine an appropriate expiration date. This deficiency impacts the stability and shelf-life determination of the drug products, potentially leading to products being distributed with unverified or inaccurate expiration dates, which could compromise their efficacy and safety over time.

These observations collectively point to issues within the facility's quality system and manufacturing controls, specifically concerning environmental monitoring, personnel hygiene/gowning, and stability testing. Addressing these deficiencies is critical for the facility to ensure compliance with cGMP regulations and to maintain the quality, safety, and efficacy of its drug products.